Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Aug 28, 2007

Inverness to Purchase Matritech for $36M

  • Inverness Medical Innovations is buying Matritech for $36 million in stock. Additionally, Matritech will receive up to $2 million payable in cash and/or stock dependent on achievement of certain revenue targets in the first year after closing.

    Matritech develops protein-based diagnostic products in cancer. The NMP22® BladderChek® Test is a point-of-care test cleared by the FDA for both the diagnosis and monitoring of bladder cancer.

    “We are excited about the addition of Matritech’s bladder cancer technology to the Inverness portfolio and look forward to realizing the market opportunities available to us through combining the Matritech products with our global distribution capabilities,” remarks Ron Zwanziger, president and CEO of Inverness.

    The BladderChek Test is based on Matritech’s nuclear matrix protein (NMP) technology, which correlates levels of NMPs in body fluids to the presence of cancer. In addition to the NMP22 protein marker, the company reports that it has discovered other proteins associated with cervical, breast, prostate, and colon cancer.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »